Use of the single-item Patient Global Impression-Severity scale as a self-reported assessment of insomnia severity
Ellen S Snyder, Peining Tao, Vladimir Svetnik, Christopher Lines, W Joseph Herring, Ellen S Snyder, Peining Tao, Vladimir Svetnik, Christopher Lines, W Joseph Herring
Abstract
We evaluated a single-item Patient Global Impression-Severity (PGI-S) scale for assessing insomnia severity during the clinical development programme for suvorexant. The analyses used data from two randomised, double-blind, placebo-controlled, 3-month, Phase III clinical trials of suvorexant in patients with Diagnostic and Statistical Manual of Mental Disorders IV criteria insomnia. Patients assessed insomnia severity during the previous week using the PGI-S, a one-item questionnaire containing six response options ranging from 0 (none) to 5 (very severe), at baseline and at Week 2, and Months 1, 2, and 3 after randomisation. The seven-item Insomnia Severity Index (ISI) and other subjective and objective assessments were also completed by patients. PGI-S responses were compared primarily with the ISI using descriptive statistics and correlations. The PGI-S demonstrated favourable measurement characteristics (validity, reliability, responsiveness and sensitivity). PGI-S scores decreased from baseline to Month 3 in a similar pattern to the ISI total score, and the Spearman correlation coefficient between PGI-S and the ISI was .73. An improvement of ≥2 points on the PGI-S defined a treatment responder, based on comparison to the ISI definition of a responder (improvement of ≥6 points). Our present findings suggest that the PGI-S is a simple but valid, reliable, responsive, sensitive, and meaningful patient-reported assessment of insomnia severity. The PGI-S may be particularly useful as a companion outcome to sleep monitoring using wearable sleep devices or smartphones in at-home settings.
Trial registration: ClinicalTrials.gov NCT01097616 NCT01097629.
Keywords: orexin; rating instruments; sleep.
© 2020 European Sleep Research Society.
References
REFERENCES
- American Psychiatric Association (2000). Diagnostic and statistical manual of mental disorders, 4th edition, text revision (DSM-IV-TR). Philadelphia, PA: American Psychiatric Association.
- Bastien, C. H., Vallieres, A., & Morin, C. M. (2001). Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Medicine, 2(4), 297-307.
- Bjelic-Radisic, V., Ulrich, D., Hinterholzer, S., Reinstadler, E., Geiss, I., Aigmueller, T., … Trutnovsky, G. (2018). Psychometric properties and validation of two global impression questionnaires (PGI-S, PGI-I) for stress incontinence in a German-speaking female population. Neurourology and Urodynamics, 37(4), 1365-1371.
- Breiman, L. F., Friedman, J. H., Olshen, R. A., & Stone, C. J. (1984). Classification and regression trees. Monterey, CA: Wadsworth & Brooks/Cole Advanced Books & Software.
- Busner, J., & Targum, S. D. (2007). The clinical global impressions scale: Applying a research tool in clinical practice. Psychiatry (Edgmont), 4(7), 28-37.
- Daniel, W. W. (1990). Spearman rank correlation coefficient. Boston, MA: PWS-Kent.
- Diener, H. C., Tassorelli, C., Dodick, D. W., Silberstein, S. D., Lipton, R. B., Ashina, M., … International Headache Society Clinical Trials Standing Committee (2019). Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition. Cephalalgia, 39(6), 687-710.
- FDA (2018). Methods to identify what is important to patients & select, develop or modify fit-for-purpose clinical outcomes assessments. Retrieved from
- Herring, W. J., Connor, K. M., Ivgy-May, N., Snyder, E., Liu, K., Snavely, D. B., … Michelson, D. (2016). Suvorexant in patients with insomnia: Results from two 3-month randomized controlled clinical trials. Biological Psychiatry, 79(2), 136-148.
- Herring, W. J., Connor, K. M., Snyder, E., Snavely, D. B., Morin, C. M., Lines, C., & Michelson, D. (2019). Effects of suvorexant on the Insomnia Severity Index in patients with insomnia: Analysis of pooled phase 3 data. Sleep Medicine, 56, 219-223.
- Snyder, E., Cai, B., DeMuro, C., Morrison, M. F., & Ball, W. (2018). A new single-item Sleep Quality Scale: Results of psychometric evaluation in patients with chronic primary insomnia and depression. Journal of Clinical Sleep Medicine, 14(11), 1849-1857.
- Viktrup, L., Hayes, R. P., Wang, P., & Shen, W. (2012). Construct validation of patient global impression of severity (PGI-S) and improvement (PGI-I) questionnaires in the treatment of men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. BMC Urology, 12, 30.
- Yalcin, I., & Bump, R. C. (2003). Validation of two global impression questionnaires for incontinence. American Journal of Obstetrics and Gynecology, 189(1), 98-101.
- Yang, M., Morin, C. M., Schaefer, K., & Wallenstein, G. V. (2009). Interpreting score differences in the Insomnia Severity Index: Using health-related outcomes to define the minimally important difference. Current Medical Research and Opinion, 25(10), 2487-2494.
Source: PubMed